GlassScriptPhysician profile
Paul Coleman
NPI 1417537671
$6,337.00
in general payments reported to CMS, 2019-2025
47 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $1,673 · 2023: $1,447 · 2024: $1,390 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,462.37 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.49 | 2021-2025 | |
| Novo Nordisk INC | $475.04 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $457.37 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $392.13 | 2022-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $288.39 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $282.57 | 2023-2025 | |
| Lundbeck LLC | $263.51 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $226.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.41 | 2022-2025 | Jardiance |
| Eisai INC. | $211.51 | 2024-2025 | |
| Abbott Laboratories | $207.38 | 2022-2024 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $201.73 | 2022-2025 | |
| Axsome Therapeutics, INC. | $178.03 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.92 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $161.00 | 2023-2025 | Trelegy Ellipta, Arexvy |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $157.06 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.38 | 2021-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $113.53 | 2021-2023 | Livalo, Seglentis |
| Amgen INC. | $106.02 | 2022-2024 | Otezla, Repatha |
| Sumitomo Pharma America, INC. | $80.43 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $72.97 | 2022-2023 | Nexletol |
| Currax Pharmaceuticals LLC | $67.02 | 2021-2023 | Contrave, Nexlizet, Nexletol |
| Amarin Pharma, INC. | $66.05 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $55.73 | 2023 | Edarbi, Horizant |
| Inspire Medical Systems, INC. | $54.08 | 2024-2025 | Inspire |
| Ironshore Pharmaceuticals INC. | $48.67 | 2022 | |
| Astellas Pharma US INC | $43.64 | 2022-2025 | Veozah |
| Shield Therapeutics INC | $41.84 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $41.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $39.39 | 2025 | Gvoke Hypopen, Keveyis |
| Sanofi-Aventis U.S. LLC | $37.05 | 2022 | |
| Biogen, INC. | $36.35 | 2021-2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $32.26 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.18 | 2025 | Xifaxan |
| Dexcom, INC. | $31.16 | 2025 | Dexcom G6 Transmitter |
| Abiomed | $27.09 | 2025 | |
| Verona Pharma, INC. | $20.78 | 2025 | Ohtuvayre |
| Seqirus USA INC | $20.60 | 2025 | Flucelvax, Fluad |
| Ardelyx, INC. | $18.95 | 2025 | Ibsrela |
| Mylan Specialty L.P. | $18.61 | 2023 | Yupelri |
| Ibsa Pharma INC. | $17.34 | 2022 | |
| Merck Sharp & Dohme LLC | $16.76 | 2022 | |
| Tris Pharma INC | $16.37 | 2023 | Dyanavel Xr |
| Boston Scientific Corporation | $16.30 | 2023 | Wavewriter Alpha Prime 16 |
| Phathom Pharmaceuticals, INC. | $13.31 | 2024 | Voquezna |
| Beta Bionics, INC. | $12.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Arbor Pharmaceuticals, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.